The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The composition of the gut microbiome can control innate and adaptive immunity and has emerged as a key regulator of tumor growth, especially in the context of immune checkpoint blockade (ICB) therapy. However, the underlying mechanisms for how the microbiome affects tumor growth remain unclear. Pancreatic ductal adenocarcinoma (PDAC) tends to be refractory to therapy, including ICB. Using a nontargeted, liquid chromatography–tandem mass spectrometry–based metabolomic screen, we identified the gut microbe–derived metabolite trimethylamine N -oxide (TMAO), which enhanced antitumor immunity to PDAC. Delivery of TMAO intraperitoneally or via a dietary choline supplement to orthotopic PDAC-bearing mice reduced tumor growth, associated with an immunostimulatory tumor-associated macrophage (TAM) phenotype, and activated effector T cell response in the tumor microenvironment. Mechanistically, TMAO potentiated the type I interferon (IFN) pathway and conferred antitumor effects in a type I IFN–dependent manner. Delivering TMAO-primed macrophages intravenously produced similar antitumor effects. Combining TMAO with ICB (anti-PD1 and/or anti-Tim3) in a mouse model of PDAC significantly reduced tumor burden and improved survival beyond TMAO or ICB alone. Last, the levels of bacteria containing CutC (an enzyme that generates trimethylamine, the TMAO precursor) correlated with long-term survival in patients with PDAC and improved response to anti-PD1 in patients with melanoma. Together, our study identifies the gut microbial metabolite TMAO as a driver of antitumor immunity and lays the groundwork for potential therapeutic strategies targeting TMAO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [170]
In the citing paper
“However, this effect appears to be context-dependent, as preclinical studies in breast159 and pancreatic cancer models160 indicate that TMAO may improve responses to ICIs (Fig. 3a).”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [160]
In the citing paper
“For instance, TMAO and its microbial precursors reprogrammed tumor-associated macrophages toward a pro-inflammatory, type I interferon (IFN)-dependent phenotype, augmenting CD8+ T-cell activity and potentiating anti-PD-1 efficacy in murine pancreatic cancer.160”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [160]
In the citing paper
“In an orthotopic PDAC mouse model, TMAO rendered tumours responsive to anti-PD-1 and anti-TIM3 antibodies170.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 2×
“M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.”
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302 · cited 2×
“Reads were aligned against a collection of CutC reference protein sequences that was downloaded through NCBI Reference Sequence Database bacterial (RefSeq), using BlastX (60) with E value < 1 × 10−7.”
MethodFast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 1×
“RNA-seq data were aligned using the bowtie2 (49) algorithm against hg19 human or mm10 mouse genome version, and the RSEM v1.”
MethodCytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179 · cited 1×
“12 software (50) was used to estimate read counts and RPKM (reads per kilobase, per million mapped reads) values using gene information from human Ensembl transcriptome version GRCh37.”
MethodIntegrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508 · cited 1×
“Cell clustering, marker identification, and visualization were performed using Seurat v4 (55).”
MethodThe Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Improved metagenomic analysis with Kraken 2
Wood, D. E., Lu, J., & Langmead, B. (2019) · Genome Biology · doi:10.1186/s13059-019-1891-0 · Cited by 7,061 · cited 1×
“Shotgun sequencing data related to response to PD1 blockade treatment after fecal microbiota transplant (14) were derived from NCBI BioProject PRJNA672867 and analyzed using Kraken2 (58) and Bracken (59) pipelines.”
MethodGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · cited 2×
“Chronic exposure to TMAO increases the risk for cardiovascular disease, renal failure, and diabetes (18, 19, 44), and increased TMAO levels are linked to risk of chronic inflammatory malignancies like colorectal cancer (45, 46).”
BackgroundAran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984 · cited 1×
“The R package SingleR (56) was used to determine cell types of the clusters using the ImmGen dataset as a reference for cell-specific gene signatures.”
MethodGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Bracken: estimating species abundance in metagenomics data
(2016) · doi:10.7717/peerj-cs.104 · Cited by 2,333
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.011 · Cited by 1,968
You are what you eat: Diet, health and the gut microbiota
Zmora, N., Suez, J., & Elinav, E. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0061-2 · Cited by 1,792 · cited 1×
“The gut microbiome produces a variety of metabolites in the process of degrading dietary factors (15); some of these can trigger inflammatory responses and thus contribute to regulating immune function and disease processes (16, 17).”
BackgroundFecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin, I., Chandra, V., San Lucas, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.008 · Cited by 1,577 · cited 6×
“(7) suggested that enrichment of several bacterial species in tumors from long-term survivors (LTS) of PDAC is predictive of improved survival.”
BackgroundMethodInfluentialMicrobiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407 · cited 1×
“The gut microbiome produces a variety of metabolites in the process of degrading dietary factors (15); some of these can trigger inflammatory responses and thus contribute to regulating immune function and disease processes (16, 17).”
BackgroundPushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C. P., Kurz, E., Mishra, A., Mohan, N., Aykut, B., Usyk, M., Torres, L. E., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1134 · Cited by 1,400
Tang, W. H. W., Wang, Z., Kennedy, D. J., Wu, Y., Buffa, J. A., Agatisa-Boyle, B., Li, X. S., Levison, B. S., & Hazen, S. L. (2015) · Circulation Research · doi:10.1161/circresaha.116.305360 · Cited by 1,223 · cited 2×
“Chronic exposure to TMAO increases the risk for cardiovascular disease, renal failure, and diabetes (18, 19, 44), and increased TMAO levels are linked to risk of chronic inflammatory malignancies like colorectal cancer (45, 46).”
BackgroundTargeting tumor-associated macrophages in cancer
Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933
Romano, K. A., Vivas, E. I., Amador-Noguez, D., & Rey, F. E. (2015) · mBio · doi:10.1128/mbio.02481-14 · Cited by 777
Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J. H., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 750
Self-citationHezaveh, K., Shinde, R. S., Klötgen, A., Halaby, M. J., Lamorte, S., Ciudad, M. T., Quevedo, R., Neufeld, L., Liu, Z. Q., Jin, R., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.006 · Cited by 746
Self-citationMicrobial conversion of choline to trimethylamine requires a glycyl radical enzyme
Craciun, S., & Balskus, E. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215689109 · Cited by 701
clusterMaker: a multi-algorithm clustering plugin for Cytoscape
Morris, J. H., Apeltsin, L., Newman, A. M., Baumbach, J., Wittkop, T., Su, G., Bader, G. D., & Ferrin, T. E. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-436 · Cited by 621 · cited 1×
“Clustering was performed using Cytoscape plugin clusterMaker2 (53) with the “Community Cluster (GLay)” option.”
MethodMicrobiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
Lam, K. C., Araya, R. E., Huang, A., Chen, Q., Di Modica, M., Rodrigues, R. R., Lopès, A., Johnson, S. B., Schwarz, B., Bohrnsen, E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.019 · Cited by 604
Chen, M., Zhu, X., Ran, L., Lang, H., Yi, L., & Mi, M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006347 · Cited by 600
Development of a gut microbe–targeted nonlethal therapeutic to inhibit thrombosis potential
Roberts, A. B., Gu, X., Buffa, J. A., Hurd, A. G., Wang, Z., Zhu, W., Gupta, N., Skye, S. M., Cody, D. B., Levison, B. S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0128-1 · Cited by 552
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
Zhang, F., Parayath, N. N., Ene, C. I., Stephan, S. B., Koehne, A. L., Coon, M. E., Holland, E. C., & Stephan, M. T. (2019) · Nature Communications · doi:10.1038/s41467-019-11911-5 · Cited by 521
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
Takenaka, M. C., Gabriely, G., Rothhammer, V., Mascanfroni, I. D., Wheeler, M. A., Chao, C.-C., Gutiérrez-Vázquez, C., Kenison, J., Tjon, E. C., Barroso, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0370-y · Cited by 517
Uncovering the trimethylamine-producing bacteria of the human gut microbiota
Rath, S., Heidrich, B., Pieper, D. H., & Vital, M. (2017) · Microbiome · doi:10.1186/s40168-017-0271-9 · Cited by 515 · cited 1×
“(30) in human fecal samples by a gene-targeted assay for choline TMA lyase (CutC).”
BackgroundInflammatory networks underlying colorectal cancer
Lasry, A., Zinger, A., & Ben-Neriah, Y. (2016) · Nature Immunology · doi:10.1038/ni.3384 · Cited by 489
McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01698-2 · Cited by 472
Immunotherapy for pancreatic cancer: A 2020 update
Schizas, D., Charalampakis, N., Kole, C., Economopoulou, P., Koustas, E., Gkotsis, E., Ziogas, D., Psyrri, A., & Karamouzis, M. V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102016 · Cited by 458
Wang, H., Rong, X., Zhao, G., Zhou, Y., Xiao, Y., Ma, D., Jin, X., Wu, Y., Yan, Y., Yang, H., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.010 · Cited by 411 · cited 2×
“For example, triple-negative breast cancers enriched with immune-activated cells contain bacteria belonging to Clostridiales and abundant levels of TMAO (17).”
BackgroundSelf-citationRole of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology
Pello, O. M., De Pizzol, M., Mirolo, M., Soucek, L., Zammataro, L., Amabile, A., Doni, A., Nebuloni, M., Swigart, L. B., Evan, G. I., et al. (2012) · Blood · doi:10.1182/blood-2011-02-339911 · Cited by 386
Wu, K., Yuan, Y., Yu, H., Dai, X., Wang, S., Sun, Z., Wang, F., Fei, H., Lin, Q., Jiang, H., et al. (2020) · Blood · doi:10.1182/blood.2019003990 · Cited by 345
Lang, D., Yeung, C., Peter, R., Ibarra, C., Gasser, R., Itagaki, K., Philpot, R., & Rettie, A. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00218-4 · Cited by 303 · cited 1×
“TMA then enters the portal circulation and undergoes oxidation to TMAO in the liver (22).”
BackgroundMicrobiota-Induced Type I Interferons Instruct a Poised Basal State of Dendritic Cells
Schaupp, L., Muth, S., Rogell, L., Kofoed-Branzk, M., Melchior, F., Lienenklaus, S., Ganal-Vonarburg, S. C., Klein, M., Guendel, F., Hain, T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.022 · Cited by 263 · cited 1×
“The type I IFN pathway has emerged as a key link between the gut microbiome and host immune responses in multiple pathophysiological situations including cancer (13, 40).”
BackgroundBae, S., Ulrich, C. M., Neuhouser, M. L., Malysheva, O., Bailey, L. B., Xiao, L., Brown, E. C., Cushing-Haugen, K. L., Zheng, Y., Cheng, T.-Y. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1835 · Cited by 253
Microscopic insights into the protein-stabilizing effect of trimethylamine N-oxide (TMAO)
Ma, J., Pazos, I. M., & Gai, F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403224111 · Cited by 252 · cited 1×
“TMAO was initially described as having a role in maintaining the structural and functional integrity of proteins (24).”
BackgroundMartínez-del Campo, A., Bodea, S., Hamer, H. A., Marks, J. A., Haiser, H. J., Turnbaugh, P. J., & Balskus, E. P. (2015) · mBio · doi:10.1128/mbio.00042-15 · Cited by 224
Jing, W., McAllister, D., Vonderhaar, E. P., Palen, K., Riese, M. J., Gershan, J., Johnson, B. D., & Dwinell, M. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0573-5 · Cited by 217 · cited 1×
“STING agonists shape TAM/myeloid cells to acquire a dominant immunostimulatory phenotype and render tumors responsive to checkpoint therapy in preclinical models of many cancer types including PDAC (34, 35).”
BackgroundShinde, R., Hezaveh, K., Halaby, M. J., Kloetgen, A., Chakravarthy, A., da Silva Medina, T., Deol, R., Manion, K. P., Baglaenko, Y., Eldh, M., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0107-1 · Cited by 201
Self-citationAgonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies
Panni, R. Z., Herndon, J. M., Zuo, C., Hegde, S., Hogg, G. D., Knolhoff, B. L., Breden, M. A., Li, X., Krisnawan, V. E., Khan, S. Q., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau9240 · Cited by 201
The exogenous origin of trimethylamine in the mouse
Al-Waiz, M., Mikov, M., Mitchell, S. C., & Smith, R. L. (1992) · Metabolism · doi:10.1016/0026-0495(92)90140-6 · Cited by 196 · cited 1×
“Generation of TMAO is completely dependent on TMA production by intestinal bacteria (23).”
BackgroundGCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment
Halaby, M. J., Hezaveh, K., Lamorte, S., Ciudad, M. T., Kloetgen, A., MacLeod, B. L., Guo, M., Chakravarthy, A., Medina, T. D. S., Ugel, S., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aax8189 · Cited by 186
Zhuang, R., Ge, X., Han, L., Yu, P., Gong, X., Meng, Q., Zhang, Y., Fan, H., Zheng, L., Liu, Z., et al. (2019) · Obesity Reviews · doi:10.1111/obr.12843 · Cited by 179 · cited 1×
“Chronic exposure to TMAO increases the risk for cardiovascular disease, renal failure, and diabetes (18, 19, 44), and increased TMAO levels are linked to risk of chronic inflammatory malignancies like colorectal cancer (45, 46).”
BackgroundPotential TMA-Producing Bacteria Are Ubiquitously Found in Mammalia
Rath, S., Rud, T., Pieper, D. H., & Vital, M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02966 · Cited by 130
Yang, K., Hou, Y., Zhang, Y., Liang, H., Sharma, A., Zheng, W., Wang, L., Torres, R., Tatebe, K., Chmura, S. J., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201915 · Cited by 124
Analysis of Myeloid Cells in Mouse Tissues with Flow Cytometry
Liu, Z., Gu, Y., Shin, A., Zhang, S., & Ginhoux, F. (2020) · STAR Protocols · doi:10.1016/j.xpro.2020.100029 · Cited by 120 · cited 1×
“Single-cell suspensions of tumor, spleen, mesenteric lymph node, bonemarrow, and colonmucosawere prepared as previously described (3, 47, 48) and stained for surface and intracellular markers.”
MethodRomieu-Mourez, R., Solis, M., Nardin, A., Goubau, D., Baron-Bodo, V., Lin, R., Massie, B., Salcedo, M., & Hiscott, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1279 · Cited by 89
Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV
Giron, L. B., Palmer, C. S., Liu, Q., Yin, X., Papasavvas, E., Sharaf, R., Etemad, B., Damra, M., Goldman, A. R., Tang, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24077-w · Cited by 82
Self-citationAger, C. R., Boda, A., Rajapakshe, K., Lea, S. T., Di Francesco, M. E., Jayaprakash, P., Slay, R. B., Morrow, B., Prasad, R., Dean, M. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003246 · Cited by 76 · cited 1×
“STING agonists shape TAM/myeloid cells to acquire a dominant immunostimulatory phenotype and render tumors responsive to checkpoint therapy in preclinical models of many cancer types including PDAC (34, 35).”
BackgroundXian, G., Zhao, J., Qin, C., Zhang, Z., Lin, Y., & Su, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.006 · Cited by 56
Type I interferons inhibit the generation of tumor-associated macrophages
U’Ren, L., Guth, A., Kamstock, D. A., & DOW, S. W. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0776-6 · Cited by 53 · cited 1×
“For example, type I IFN activation has been suggested to restrict generation of TAMs while promoting polarization toward the immunostimulatory phenotype (13, 33).”
Background
Cited by
Ma, Z., Zuo, T., Frey, N., & Rangrez, A. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01946-6 · Cited by 259
“602,603 Although GF mice display anxiety-like behaviors (see discusstion in the section on the germ-free syndrome), certain gut bacteria strains, such as Bacteroides ovatus , metabolize dietary tyrosine into p-coumaric acid via the enzyme tyrosine ammonia lyase (encoded by BACOVA_01194).”
BackgroundA Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Barriers and opportunities in pancreatic cancer immunotherapy
Ju, Y., Xu, D., Liao, M.-M., Sun, Y., Bao, W.-D., Yao, F., & Ma, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00681-z · Cited by 159
“When combined with anti-PD-1 therapy, TMAO delivery led to a signi fi cant reduction in tumor burden and prolonged survival compared with treatment with TMAO or ICB alone 102 .”
BackgroundModulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Kang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101478 · Cited by 198
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Metadata
- Authors
- Mirji, G., Worth, A., Bhat, S. A., El Sayed, M., Kannan, T., Goldman, A. R., Tang, H.-Y., Liu, Q., Auslander, N., Dang, C. V., Abdel-Mohsen, M., Kossenkov, A., Stanger, B. Z., & Shinde, R. S.
- Affiliations
- The Wistar Institute (US)
- Immunology, Microenvironment and Metastasis Program, the Wistar Institute, Philadelphia, PA, USA.
- University of Pennsylvania (US)
- Corresponding author
- Shinde, Rahul S.
- ORCID
- Venue
- Science Immunology
- Published
- 2022-09-30
- Volume
- 7
- Issue
- 75
- Pages
- eabn0704-eabn0704
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC9925043
- OpenAlex
- W4295519447
- Cited by
- 327
- References
- 62
- Citations by year
- 2026: 83 · 2025: 91 · 2024: 89 · 2023: 62 · 2022: 2
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (1s10od023586-01)
- National Cancer Institute (R01CA057341, R21CA259240, R50CA221838, R50CA211199, R01CA252225, P30CA010815)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- trimethylamine N-oxide, gut microbiota, pancreatic ductal adenocarcinoma, immune checkpoint blockade, antitumor immunity, tumor-associated macrophages, type I interferon pathway, choline, CutC, anti-PD-1, effector T cells, tumor microenvironment, melanoma
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Methylamines, Pancreatic Neoplasms, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.